

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

*Amendments*

*In the Claims:*

Please amend the claims as follows:

(a) Please cancel claims 10 and 29-32, without prejudice to or disclaimer of the subject matter contained therein. Applicants reserve the right to prosecute the subject matter of these claims in one or more continuing applications.

(b) Please enter the following new claims 34-37:

34. (New) The purified uricase of claim 1, wherein said uricase contains no more than about 2% of aggregates larger than octamers.

35. (New) The uricase conjugate of claim 17, wherein said uricase contains no more than about 2% of aggregates larger than octamers.

36. (New) The pharmaceutical composition of claim 27, wherein said uricase contains no more than about 2% of aggregates larger than octamers.

*B1  
Cont*  
37. (New) A purified fragment of uricase that contains no more than about 2% of aggregates larger than octamers, wherein said fragment is a recombinant uricase that has been truncated at the amino terminus, at the carboxyl terminus, or at both the amino and carboxyl termini.

(c) Please amend the remaining claims as follows:

Please substitute the following claim 5 for currently pending claim 5:

*B2*  
5. (Once amended) The uricase of Claim 4, wherein the uricase has the sequence of porcine, bovine, ovine or baboon liver uricase.

Please substitute the following claim 9 for currently pending claim 9:

*B3*  
9. (Twice amended) The uricase of Claim 4, wherein the uricase has the sequence as set forth in SEQ ID NO:2, wherein tyrosine 97 has been replaced by histidine.

Please substitute the following claim 12 for currently pending claim 12:

*B4*  
12. (Once amended) The uricase of Claim 11, wherein the fungal or microbial uricase is isolated from *Aspergillus flavus*, *Arthrobacter globiformis*, *Bacillus sp.* or *Candida utilis*, or is a recombinant enzyme having the sequence of one of said uricases.

Please substitute the following claim 14 for currently pending claim 14:

*B5*  
14. (Once amended) The uricase of Claim 13, wherein the invertebrate uricase is isolated from *Drosophila melanogaster* or *Drosophila pseudoobscura*, or is a recombinant enzyme having the sequence of one of said uricases.

Please substitute the following claim 16 for currently pending claim 16:

16. (Once amended) The uricase of Claim 15, wherein the plant uricase is isolated from root nodules of *Glycine max* or is a recombinant enzyme having the sequence of said uricase.

*B6*  
[Please substitute the following claim 17 for currently pending claim 17.]

17. (Once amended) A uricase conjugate comprising the uricase of Claim 1 conjugated to poly(ethylene glycol) or poly(ethylene oxide).

Please substitute the following claim 19 for currently pending claim 19:

*B7*  
19. (Once amended) The uricase conjugate of Claim 17, wherein said uricase is conjugated to said poly(ethylene glycol) or poly(ethylene oxide) via a linkage selected from the group consisting of urethane (carbamate), secondary amine and amide.

Please substitute the following claim 33 for currently pending claim 33:

*Sur C*  
*B8*  
33. (Once amended) Isolated uricase prepared by a method comprising separating uricase aggregates larger than octamers from uricase tetramers and octamers and excluding such aggregates from the isolated uricase.